Physicochemical Properties
| Molecular Formula | C27H23BRN4O2S |
| Molecular Weight | 547.47 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | In musle L6 cells, GSK-3β inhibitor 7 (Compound 6x, 5 μM, 3 h) exhibits a high rate of glucose absorption (83.5%)[1]. GSK-3β is inhibited by GSK-3β inhibitor 7 (0-30 μM, 30 min) with an IC50 value of 5.25 μM[1]. |
| ln Vivo | In rats, GSK-3β inhibitor 7 (Compound 6x, oral administration, 20 mg/kg) exhibits good oral bioavailability and drug-like characteristics (t1/2: 5.4 h, Cmax: 507 ng/mL)[1]. Mice given 1 g/kg of GSK-3β inhibitor 7 intragastrically show no signs of acute toxicity[1]. |
| Animal Protocol |
Animal/Disease Models: SD (Sprague-Dawley) rats (pharmacokinetic/PK assay)[1] Doses: 2 mg/kg, 20 mg/kg Route of Administration: intravenous (iv) injection (2 mg/kg), oral administration (20 mg/kg) Experimental Results: pharmacokinetic/PK profile of GSK-3β inhibitor 7 (Compound 6x). Compound Route Dose (mg/kg) t1/2 (h ) Tmax (h) Cmax (ng/mL) AUC0-t (hr·ng/mL) AUC0-∞ (hr·ng/mL) CL (mL/hr/kg) F (%) GSK-3β inhibitor 7 Oral administration 20 5.40 1.67 507 4265 4501 4536 47.4 GSK-3β inhibitor 7 intravenous (iv) injection 2 8.95 0.08 519 859 948.6 2138.66 F: oral bioavailability. Animal/Disease Models: Male and female mice (acute assay)[1] Doses: 1 g/kg Route of Administration: intragastric (po) administration Experimental Results: Increased body weights, caused no death or obvious weight loss. demonstrated no marked pathological damage in important organs (brain, heart, liver, spleen, lung, and kidney). |
| References |
[1]. Structure-Based design of Marine-derived Meridianin C derivatives as glycogen synthase kinase 3β inhibitors with improved oral bioavailability: From aminopyrimidyl-indoles to the sulfonyl analogues. Bioorg Chem. 2022 Feb;119:105537. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8266 mL | 9.1329 mL | 18.2658 mL | |
| 5 mM | 0.3653 mL | 1.8266 mL | 3.6532 mL | |
| 10 mM | 0.1827 mL | 0.9133 mL | 1.8266 mL |